Cipla South Africa CEO, Paul Miller

Cipla Medpro South Africa has concluded an
exclusive agreement to secure the originator and authorised generic brands of the
atypical anti-psychotic drug, Quetiapine.

 The agreement involving the
originator of the drug, AstraZeneca Pharmaceuticals, the originator of
the drug, and Luye Pharma Hong Kong allows Cipla Medpro to market and
distribute the medicine in South Africa and neighbouring countries.

 The existing portfolio consists of
the originator brand Seroquel® and the authorised generic brand Truvalin®,
which are used to treat mental health conditions such as schizophrenia, bipolar
disorder, and major depressive disorder.

 Paul Miller, CEO of Cipla South
Africa, said the agreement strategically enhances Cipla’s Central Nervous
System (CNS) portfolio: “We want people to live a long and healthy life and
have invested significantly in public awareness campaigns to educate people
about the importance of mental health and the fact that there is help and hope.
This transaction will help ensure that people have access to affordable and
quality medicine that will help improve quality of life for people living with
these conditions.”

 “This partnership amplifies Cipla’s
growing intent to partner with innovator companies and this is a further
demonstration of our core competence in building and growing originator brands,
ably strengthened by strong corporate governance and quality mindset,” said
Miller.

 

Source: Cipla